OTLK Outlook Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OTLK

Price (delayed)

$8.5

Market cap

$110.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4

Enterprise value

$136.8M

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME ...

Highlights
The EPS has grown by 35% YoY and by 17% from the previous quarter
The net income has grown by 27% YoY and by 13% from the previous quarter
The quick ratio has dropped by 93% year-on-year and by 54% since the previous quarter
Outlook Therapeutics's equity has shrunk by 69% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://outlooktherapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of OTLK
Market
Shares outstanding
13.01M
Market cap
$110.61M
Enterprise value
$136.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$52.57M
EBITDA
-$52.51M
Free cash flow
-$47.1M
Per share
EPS
-$4
Free cash flow per share
-$3.62
Book value per share
-$1.87
Revenue per share
$0
TBVPS
$1.67
Balance sheet
Total assets
$21.68M
Total liabilities
$46.03M
Debt
$36.55M
Equity
-$24.34M
Working capital
-$25.58M
Liquidity
Debt to equity
-1.5
Current ratio
0.44
Quick ratio
0.23
Net debt/EBITDA
-0.5
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-135.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OTLK stock price

How has the Outlook Therapeutics stock price performed over time
Intraday
0%
1 week
3.79%
1 month
-12.37%
1 year
665.77%
YTD
2,057.36%
QTD
-28.81%

Financial performance

How have Outlook Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$47.76M
Net income
-$51.5M
Gross margin
N/A
Net margin
N/A
The net income has grown by 27% YoY and by 13% from the previous quarter
OTLK's operating income is up by 27% YoY and by 10% QoQ

Growth

What is Outlook Therapeutics's growth rate over time

Valuation

What is Outlook Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 35% YoY and by 17% from the previous quarter
Outlook Therapeutics's equity has shrunk by 69% QoQ

Efficiency

How efficient is Outlook Therapeutics business performance
The company's return on assets fell by 11% QoQ but it rose by 5% YoY

Dividends

What is OTLK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OTLK.

Financial health

How did Outlook Therapeutics financials performed over time
OTLK's total assets is 53% smaller than its total liabilities
The quick ratio has dropped by 93% year-on-year and by 54% since the previous quarter
The current ratio has plunged by 89% YoY and by 33% from the previous quarter
OTLK's debt to equity has dropped by 174% year-on-year but it is up by 39% since the previous quarter
Outlook Therapeutics's equity has shrunk by 69% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.